Skip to content

Nuvation Bio Inc.

Location not on file

OncologyGrant-onlyListed · NUVB

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Study registered, no phase assigned: Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

6mo agoTrial registeredDec 24, 2025Source filing (opens the source filing in a new tab)

Momentum

48no change

Momentum 48 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources